31698-56-3

Usage

Uses

Used in Pharmaceutical Industry:
Quinoline, 8-fluoro-4-methylis used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activity. Its unique structure allows for the development of new drugs and other biologically active molecules, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, Quinoline, 8-fluoro-4-methylis utilized as a precursor in the production of agrochemicals. Its chemical properties make it suitable for the creation of compounds that can be used in pest control and crop protection, thereby enhancing agricultural productivity.
Used in Medicinal Chemistry Research:
Quinoline, 8-fluoro-4-methylis employed as a subject of interest in medicinal chemistry research. Its unique structure and properties are studied to understand its potential applications in the development of new therapeutic agents and to explore its interactions with biological systems.

Upstream product

• 491-35-0 C₆H₄NCH₂CHCCH₂ 
• 348-54-9 2-Fluoroaniline 
• 78-94-4 methyl vinyl ketone 

Downstream Products

• 496792-30-4 8-fluoro-4-quinolinecarboxaldehyde 

Relevant academic research and scientific papers

Discovery of an Inhibitor of the Proteasome Subunit Rpn11

The proteasome plays a crucial role in degradation of normal proteins that happen to be constitutively or inducibly unstable, and in this capacity it plays a regulatory role. Additionally, it degrades abnormal/damaged/mutant/misfolded proteins, which serves a quality-control function. Inhibitors of the proteasome have been validated in the treatment of multiple myeloma, with several FDA-approved therapeutics. Rpn11 is a Zn2+-dependent metalloisopeptidase that hydrolyzes ubiquitin from tagged proteins that are trafficked to the proteasome for degradation. A fragment-based drug discovery (FBDD) approach was utilized to identify fragments with activity against Rpn11. Screening of a library of metal-binding pharmacophores (MBPs) revealed that 8-thioquinoline (8TQ, IC50 value ～2.5 μM) displayed strong inhibition of Rpn11. Further synthetic elaboration of 8TQ yielded a small molecule compound (35, IC50 value ～400 nM) that is a potent and selective inhibitor of Rpn11 that blocks proliferation of tumor cells in culture.

INHIBITORS OF RPN11

Candidate compounds for specific inhibition of Rpn11 are represented by Formula 1a where each of R2, R3, R4, R5, R6, and R7 is independently selected from hydrogen (H), substituted and unsubstituted alkyl groups, carboxyl groups, or substituted and unsubstituted carboxyamides.

QU1NOLINE DERIVATIVES AND THEIR USES FOR RHINITIS AND URTICARIA

The present invention relates to compounds of formula (I) and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various diseases, such as allergic rhinitis.

Optimization of a dihydropyrrolopyrazole series of transforming growth factor-β type I receptor kinase domain inhibitors: Discovery of an orally bioavailable transforming growth factor-β receptor type I inhibitor as antitumor agent

In our continuing effort to expand the SAR of the quinoline domain of dihydropyrrolopyrazole series, we have discovered compound 15d, which demonstrated the antitumor efficacy with oral bioavailability. This effort also demonstrated that the PK/PD in vivo target inhibition paradigm is an effective approach to assess potential for antitumor efficacy. The dihydropyrrolopyrazole inhibitor 15d (LY2109761) is representative of a novel series of antitumor agents.

AN IMPROVED PROCESS FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES

The present invention provides an improved process for the synthesis of quinoline derivatives. More particularly the present invention provides an improved and economical process for the synthesis of quinoline derivatives by the reaction of aniline/substituted anilines using two different catalysts, ferric chloride and zinc chloride in a one-pot set up reaction.

Process for the synthesis of quinoline derivatives

The present invention provides an improved process for the synthesis of quinoline derivatives. More particularly the present invention provides an improved and economical process for the synthesis of quinoline derivatives by the reaction of aniline/substituted anilines using two different catalysts, ferric chloride and zinc chloride in a one-pot set up reaction.

THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE

The invention relates to thienopyrimidinediones of formula (1) wherein R1 and R2 each independently represent a C1-6akyl, C3-6alkyl, C3-6alkenyl, C3-5cycloalkylC1-3alkyl or Csub

Elemental fluorine Part 15. Selective direct fluorination of quinoline derivatives

Direct fluorination of various quinoline derivatives in acidic reaction media gives fluorinated quinoline products arising from electrophilic substitution processes.